Composite supplier scorecard combining FDA inspection class, active DMF count, trade volume, and enforcement status. Rank candidates in one query.
Micro Labs leads the apixaban scorecard with $7.5M in 2025 exports, two active Type II DMFs, an NAI-cleared API plant, and zero active enforcement. Intas Pharmaceuticals and Macleods follow with comparable composites. The bottom tier carries DMFs but thin or absent trade, the paper-only supplier signal.
| # | Supplier | Inspection | Active DMFs | 2025 exports | Composite tier |
|---|---|---|---|---|---|
| 1 | Micro Labs | IN · Bengaluru | 2 DMFs | $7.5M · 2025 | NAI |
| 2 | Intas Pharmaceuticals | IN · Ahmedabad | 2 DMFs | $4.6M · 2025 | VAI |
| 3 | Macleods Pharmaceuticals | IN · Mumbai | 2 DMFs | $4.4M · 2025 | VAI |
| 4 | Cadila Pharmaceuticals | IN · Ahmedabad | 1 DMFs | $2.8M · 2025 | NAI |
| 5 | Natco Pharma | IN · Hyderabad | 1 DMFs | $2.5M · 2025 | VAI |
| 6 | Hetero Labs | IN · Hyderabad | 2 DMFs | $2.5M · 2025 | VAI |
| 7 | Dr Reddy's Laboratories | IN · Hyderabad | 1 DMFs | $1.8M · 2025 | NAI |
| 8 | MSN Life Sciences | IN · Hyderabad | 2 DMFs | $0.5M · 2025 | VAI |
Type the INN. The AI agent pulls every supplier with an active FDA Type II DMF, EDQM CEP, or attested plant for that molecule.
Composite blends four signals: inspection class (NAI/VAI/OAI), active DMF count, recent trade volume, and active enforcement events.
Citation-anchored brief with the ranked cohort, sub-scores per pillar, and a chip showing any active warning letter or import alert.
Inspection class alone misses paper-only DMF holders. Trade alone misses dossier-thin shippers. The composite catches both failure modes.
Active warning letters, import alerts, and consent decrees show as a red chip on the row. A buyer never sees a scored row that's quietly under enforcement.
Suppliers with active DMFs but zero recent exports are flagged as paper-only. They are not in the qualifiable pool.
Inspection feed, trade aggregates, and enforcement status all refresh weekly. The composite reruns on every refresh.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twenty molecules · count of scored, qualifiable suppliers (active DMF + non-zero recent trade), 2026 snapshot.
The supplier scorecard is the first ranking of a qualifiable supplier pool. PharmaDB joins regulatory dossiers, inspection class, trade volume, and enforcement status at the supplier entity so the score is one query, not a multi-team spreadsheet exercise. The view rests on api_docs, inspections, company_trade_exports_by_molecule, and compliance_events. Refresh cadence is weekly.
Four pillars: FDA inspection class (NAI weighted highest, OAI excluded), active DMF or CEP count, recent trade volume in USD, and an enforcement penalty for active warning letters or import alerts. Weights are configurable per buyer; the default reflects API procurement priorities.
The supplier-level composite uses the best inspection class among active plants attributed to the supplier, and the sum of active DMFs across them. Plant-level detail is one click below the row.
A supplier with an active DMF but no recent shipments on the molecule-lane is paper-only. PharmaDB surfaces them separately because their dossier exists but the supply chain to support an RFQ may not.
Yes. The pool is the union of active FDA Type II DMFs, EDQM CEPs, and plant-attested API suppliers. Buyers sourcing for EU markets see the same composite applied to CEP holders.
Active enforcement events show as a red chip on the supplier row, with the date and the regulator. A supplier under active enforcement is never silently scored well; the chip is unmissable.
Weekly. Inspection feed, trade aggregates, and enforcement publications all refresh weekly. The composite reruns on every refresh; the catalog row carries an as-of timestamp.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.